

2018–2019 POCC Lecture Series

November 29, 2018, 7:30 PM

6:30 reception in the Nobel Hall

Sponsored by Fox Chase Chemical Diversity Center

Dr. Pamela A. Haile


GlaxoSmithKline

*Identification of a first-in-class RIP2 kinase inhibitor
in phase 1 clinical trials for immuno-inflammatory
diseases: Small Molecules and Beyond*

Carolyn Hoff Lynch Lecture Hall
Chemistry Building, University of Pennsylvania



The Philadelphia
Organic Chemist's
Club



POCClub.org

Pamela completed her B.S. in chemistry in 1998 at Hendrix College in Conway, Arkansas, followed by a Ph.D. under Professor Michael Crimmins in synthetic chemistry at the University of North Carolina–Chapel Hill in 2004. Pamela then moved to the University of California–Irvine for post-doctoral research with Professor Keith Woerpel, before then joining GSK in 2006 at Upper Providence, Pennsylvania. Pamela is currently a GSK Fellow and Scientific Leader at GSK focused on inhibitors of pattern recognition receptor pathways.

Abstract: Receptor interaction protein 2 (RIP2) kinase activity is a central component of the innate immune system signaling downstream of pattern recognition receptors NOD1 and NOD2. RIP2 kinase has been identified as a therapeutic target for a variety of inflammatory diseases. We have identified a first-in-class RIP2 small molecule inhibitor through kinase focused and DNA-encoded library screening as well RIP2 protein degraders utilizing Protac technology. This presentation will highlight the lead optimization and SAR that led to identification of the development candidate prodrug GSK559 now under phase 1 clinical evaluation. Efforts toward a RIP2 Protac will also be discussed.